Literature DB >> 211313

Control of plasma aldosterone in a patient with Conn's syndrome before and during spironolactone medication.

H Vetter, W Vetter.   

Abstract

In a patient suffering from Conn's syndrome analysis of short-time fluctuations of plasma aldosterone, plasma cortisol and plasma renin activity were performed before and after a 9-months therapy period with spironolactone. Under the former conditions aldosterone was secreted episodically and a highly significant correlation was found between plasma aldosterone and plasma cortisol (r=0.817, p is less than 0.001) while plasma renin activity was undetectable (is less than 0.16 ng/ml/3hr). Following a 9-month therapy with spironolactone episodic secretion of aldosterone and the significant correlation between aldosterone and cortisol persisted (r=0.819, p less than 0.001) in the presence of an abnormally high plasma renin activity. First when the secretion of ACTH was suppressed by dexamethasone a weak correlation was found between renin activity and aldosterone (r=0.517, p is less than 0.05). Our results show that both before and after a 9-months therapy with spironolactone episodic aldosterone release of an aldosterone producing adrenal adenoma was mediated through ACTH and that endogeneous angiotensin II had no or only little influence.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 211313     DOI: 10.1007/bf01468678

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  16 in total

1.  SUPPRESSION OF PLASMA RENIN ACTIVITY IN PRIMARY ALDOSTERONISM.

Authors:  J W CONN; E L COHEN; D R ROVNER
Journal:  JAMA       Date:  1964-10-19       Impact factor: 56.272

2.  Episodic secretion of aldosterone in primary aldosteronism: relationship to cortisol.

Authors:  H Vetter; M Berger; H Armbruster; W Siegenthaler; C Werning; W Vetter
Journal:  Clin Endocrinol (Oxf)       Date:  1974-01       Impact factor: 3.478

3.  [Suppression and stimulation of plasma renin concentration in primary hyper-aldosteronism].

Authors:  R Beckerhoff; R Wilkinson; J A Luetscher; W Vetter; W Siegenthaler
Journal:  Klin Wochenschr       Date:  1972-08-15

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Radioimmunoassay of ACTH in plasma.

Authors:  S A Berson; R S Yalow
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

6.  Suppressed plasma renin activity in hypertension.

Authors:  B J Channick; E V Adlin; A D Marks
Journal:  Arch Intern Med       Date:  1969-02

7.  Radioimmunoassay for aldosterone without chromatography. 2. Determination of plasma aldosterone.

Authors:  W Vetter; H Vetter; W Siegenthaler
Journal:  Acta Endocrinol (Copenh)       Date:  1973-11

8.  Primary aldosteronism with suppressed plasma renin activity due to bilateral nodular adrenocortical hyperplasia.

Authors:  F H Katz
Journal:  Ann Intern Med       Date:  1967-11       Impact factor: 25.391

9.  Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism.

Authors:  D C Kem; M H Weinberger; C Gomez-Sanchez; N J Kramer; R Lerman; S Furuyama; C A Nugent
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

10.  Stimulation and suppression of aldosterone in plasma of normal man and in primary aldosteronism.

Authors:  R Horton
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

View more
  2 in total

1.  Influence of spironolactone on serum corticosteroids in primary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; W Oelkers
Journal:  Klin Wochenschr       Date:  1979-02-15

2.  Adrenal scintigraphy in primary aldosteronism. Spironolactone as a cause of incorrect classification between adenoma and hyperplasia.

Authors:  M Fischer; W Vetter; B Winterg; W Zidek; H Vetter
Journal:  Eur J Nucl Med       Date:  1982
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.